Known targets — ChEMBL curated mechanism
DRD2DRD3HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7
The experimentally established mechanism targets of Amisulpride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | DRD1 | P21728 | 2/20 | 0.66 |
| ▸ | DRD4 | P21917 | 2/20 | 0.66 |
| ▸ | CA9 | Q16790 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amisulpride SCHEMBL29508640 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL20206474 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29508664 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL6403721 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL675545 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29506665 | 1.00 | DRD2 (1.00) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL21046204 | 0.99 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL21046205 | 0.99 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL20660127 | 0.99 | DRD2 (0.98) | DRD2DRD3TSHRADRA2BADRA2C | |
| Amisulpride SCHEMBL29083722 | 0.98 | DRD2 (0.96) | DRD2DRD3TSHRADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12148 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | claimed |
| EP-4699659-A2 | CRYSTALLINE FORMS OF EVENAMIDE | Newron Pharmaceuticals S.p.A. (IT) | 2026-02-25 | — | — | EP | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-4615820-B1 | CRYSTALLINE FORMS OF EVENAMIDE | NEWRON PHARM SPA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4678237-A2 | 5-HT7 ANTAGONIST FOR THE TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES | Medizinische Hochschule Hannover (MHH) (DE) | 2026-01-14 | — | — | EP | claimed |
| CN-1251526-A | New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders | AKZO NOBEL NV (NL) | 2000-04-26 | — | — | CN | claimed |
| EP-0983065-A1 | GASTRIC-RETAINED PHARMACEUTICAL COMPOSITION | SANOFI-SYNTHELABO (FR) | 2000-03-08 | — | — | EP | claimed |
| WO-2000003740-A2 | USE OF (S) (-)-AMISULPRIDE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF SCHIZOPHRENIA | SANOFI-SYNTHELABO (FR) | 2000-01-27 | — | — | WO | claimed |
| EP-0969845-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | Akzo Nobel N.V. (NL) | 2000-01-12 | — | — | EP | claimed |
| EP-0927026-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AMISULPRIDE AND THEIR THERAPEUTIC APPLICATIONS | SYNTHELABO (FR) | 1999-07-07 | — | — | EP | claimed |
| WO-1999021422-A1 | TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS | CORTEX PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1998047506-A1 | GASTRIC-RETAINED PHARMACEUTICAL COMPOSITION | SANOFI-SYNTHELABO (FR) | 1998-10-29 | — | — | WO | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
| WO-1998011881-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AMISULPRIDE AND THEIR THERAPEUTIC APPLICATIONS | SYNTHELABO (FR) | 1998-03-26 | — | — | WO | claimed |
| US-4401822-A | ANISEROTONINE AGENTS; APOMORPHINE ANTAGONIST | SOCIETE DE'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE FRANCE (FR) | 1983-08-30 | — | — | US | claimed |